On the stock market since 2012, it operates in the world of health and science. It has 35 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
There is $59.9M in the vault; even if every debt were paid off, $59.7M would remain.
Over the last 12 months, company executives reported 33 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $32.8M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, DMAC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: DMAC is a high-risk stock — not yet profitable, and its future rides on its product catching on.